Short Communication Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/haematology.1.001
Targeting Amino Acids to Treat AML
Xuan Zhou1, Bei Cao1,*, Juan Li1,*
- 1Phase I Clinical Trials Unit, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China
Corresponding Author
Bei Cao, cb_cpu@163.com
Juan Li, juanli2003@163.com
Received Date: May 11, 2020
Accepted Date: June 11, 2020
Zhou X, Cao B, Li J. Targeting Amino Acids to Treat AML. J Clin Haematol. 2020; 1(1):1-6.
Copyright: © 2020 Zhou X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan
Balanced translocation resulting in fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2 is the pathognomonic molecular driver of CML. The resulting BCRABL 1 fusion gene is both the diagnostic as well as therapeutic target of CML. The first agent with tyrosine kinase inhibitor activity that was licenced in 2000 for treatment of CML patients, was Imatinib, gradually followed by multiple agents with higher efficacy.
Molecular Biology for BCR-ABL1 Quantification for Chronic Myeloid Leukemia Monitorization and Evaluation
Chronic Myeloid Leukemia (CML) is a clonal disorder originated by a pluripotent hematopoietic stem cell, which presents the translocation t(9;22) (q34;q11) in 90% of the cases.
Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
Leukemia is the most common childhood malignancy and is the most common cause of cancer death before the age of 20. Pediatric leukemia can be subdivided into acute versus chronic and lymphoid versus myeloid leukemia.
Targeting Amino Acids to Treat AML
Acute myeloid leukemia (AML), a life-threatening disease, is a malignant disorder of the bone marrow characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells. It is a highly heterogeneous disease and shows differential prognosis ranging from death within a few days of beginning treatment to complete remission. Systems biology approaches such as genomics and proteomics have already greatly facilitated the leukemia typing and prognosis stratification, which boosted the personalized medicine. However, the actual clinical outcome of patients is not always inconsistent with the current AML-stratification system. Moreover, AML subtypes especially relapse or refractory AML.
Toward Integrated Genomic Diagnosis in Routine Diagnostic Pathology by the World Health Organization Classification of Acute Myeloid Leukemia
Significant milestones and seminal discoveries during 1674-1966, by individuals who have made crucial contributions toward progress in the diagnosis of hematologic neoplasms as we understand today are depicted chronologically. It is notable that the path to progress in the understanding of disease and neoplasms initially took centuries for significant discoveries (17th-18th centuries), and subsequently, many decades (19th-20th centuries) for a breakthrough or a change from the prevailing norm.